Benzinga · Sep 16, 2026
DN
NYSE · DNA
Ginkgo Bioworks Holdings, Inc.
Healthcare · Biotechnology
$7.06
Up+$0.07 (+1.00%)
Updated Sep 17, 2026, 5:51 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 539.91M
- P/E ratio
- -1.62
- Dividend yield
- 0.00%
- 52-week range
- $5.37 – $17.58
- Volume
- 976.22K
- Avg. volume
- 1.4M
Price performance
DNA price history
1M range · 20 trading sessions · Daily adjusted prices
DNA closed at $7.06 after 20 trading sessions, down 8.43% for the selected period.
- Last close
- $7.06
- Period change
- -8.43%
- Period low
- $6.75
- Period high
- $7.71
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $7.10 | $7.3909 | $6.95 | $7.06 | 976.22K |
| Sep 15, 2026 | $6.95 | $7.18 | $6.91 | $6.99 | 734.93K |
| Sep 14, 2026 | $6.66 | $7.14 | $6.66 | $7.01 | 1.03M |
| Sep 11, 2026 | $6.80 | $6.83 | $6.52 | $6.75 | 932.66K |
| Sep 10, 2026 | $6.72 | $6.85 | $6.59 | $6.78 | 679.47K |
| Sep 9, 2026 | $6.83 | $6.93 | $6.72 | $6.79 | 894.18K |
| Sep 8, 2026 | $7.00 | $7.06 | $6.75 | $6.94 | 1.08M |
| Sep 4, 2026 | $6.80 | $6.97 | $6.74 | $6.95 | 656.66K |
| Sep 3, 2026 | $7.16 | $7.22 | $6.76 | $6.95 | 860.36K |
| Sep 2, 2026 | $6.92 | $7.2986 | $6.77 | $7.03 | 1.27M |
| Sep 1, 2026 | $6.66 | $6.985 | $6.62 | $6.93 | 1.81M |
| Aug 31, 2026 | $6.90 | $6.96 | $6.67 | $6.81 | 1.21M |
| Aug 28, 2026 | $7.23 | $7.285 | $6.91 | $6.96 | 1.26M |
| Aug 27, 2026 | $7.34 | $7.43 | $7.17 | $7.26 | 757.66K |
| Aug 26, 2026 | $7.33 | $7.47 | $7.19 | $7.23 | 628.79K |
| Aug 25, 2026 | $6.94 | $7.63 | $6.86 | $7.54 | 1.68M |
| Aug 24, 2026 | $7.25 | $7.305 | $6.75 | $6.78 | 1.08M |
| Aug 21, 2026 | $7.09 | $7.42 | $6.82 | $7.40 | 1.44M |
| Aug 20, 2026 | $7.45 | $7.645 | $6.925 | $6.96 | 1.42M |
| Aug 19, 2026 | $6.98 | $7.7485 | $6.95 | $7.71 | 2.47M |
Latest DNA news
The latest Smart Investors Daily articles mentioning DNA.
Stock researchCompany · Overview
DNA research
Overview
Company profile and research snapshot.
Company profile
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 4, 2026 | BTIG | Sell | — |
| Aug 7, 2026 | TD Cowen | Hold | — |
| Mar 12, 2026 | BTIG | Sell | — |
| Jan 8, 2026 | TD Cowen | Buy | — |
| Aug 25, 2025 | BTIG | Sell | — |
News briefing
No generated briefing is available yet.
Fintel · Sep 16, 2026
Ginkgo Bioworks Holdings Consensus Price Target Cut by 22.22% to $7.14
Yahoo · Sep 10, 2026
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
BOSTON, September 10, 2026--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health’s (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime contractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale, Continuous-flow manufacturing Apparatus to Launch A Transformational Overhaul for RNA medicines), a m
Benzinga · Sep 4, 2026
BTIG Reiterates Sell on Ginkgo Bioworks Holdings, Maintains $5 Price Target
BTIG analyst Mark Massaro reiterates Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and maintains $5 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
